Antiangiogenetic Therapy with Pioglitazone, Rofecoxib, and Metronomic Trofosfamide in Patients with Advanced Malignant Vascular Tumors

Cancer

Volumn 98, Issue 10, 2003, Pages 2251-2256

  Vogt, Thomas ^a   Hafner, Christian ^a   Bross, Klaus ^a   Bataille, Frauke ^a   Jauch, Karl Walter ^b   Berand, Anna ^a   Landthaler, Michael ^a   Andreesen, Reinhard ^a   Reichle, Albrecht ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Angiosarcoma; Antiangiogenetic; Biomodulating drugs; Malignant vascular tumor; Palliative treatment

Indexed keywords

ALPHA INTERFERON; DACARBAZINE; DOXORUBICIN; IFOSFAMIDE; PIOGLITAZONE; ROFECOXIB; TROFOSFAMIDE;

ADULT; ADVANCED CANCER; AGED; ANGIOSARCOMA; ARTICLE; CANCER PALLIATIVE THERAPY; CANCER REGRESSION; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; EDEMA; FEMALE; FEVER; HEMANGIOENDOTHELIOSARCOMA; HOSPITALIZATION; HUMAN; INFECTION; KIDNEY DYSFUNCTION; LEUKOCYTE COUNT; LEUKOPENIA; MALE; PILOT STUDY; PRIORITY JOURNAL; SIDE EFFECT; SURVIVAL TIME; THRUSH; VASCULAR TUMOR;

ADMINISTRATION, ORAL; ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HEMANGIOENDOTHELIOMA; HEMANGIOSARCOMA; HUMANS; LACTONES; MALE; MIDDLE AGED; SULFONES; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 0242526860     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11775     Document Type: Article

References (28)

1. Mark RJ, Poen JC, Tran LM, Fu YS, Juillard GF. Angiosarcoma. A report of 67 patients and a review of the literature. Cancer. 1996;77:2400-2406.
2. Ferrari A, Casanova M, Bisogno G, et al. Malignant vascular tumors in children and adolescents: a report from the Italian and German Soft Tissue Sarcoma Cooperative Group. Med Pediatr Oncol. 2002;39:109-114.
3. Wollina U, Fuller J, Graefe T, Kaatz M, Lopatta E. Angiosarcoma of the scalp: treatment with liposomal doxorubicin and radiotherapy. J Cancer Res Clin Oncol. 2001;127:396-399.
4. Van Glabbeke M, Verweij J, Judson I, Nielsen OS. Progression-free rate as the principal end-point for Phase II trials in soft-tissue sarcomas. Eur J Cancer. 2002;38:543-549.
5. Eralp Y, Bavbek S, Basaran M, et al. Prognostic factors and survival in late adolescent and adult patients with small round cell tumors. Am J Clin Oncol. 2002;25:418-424.
6. Klement G, Baruchel S, Rak J, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest. 2000;105:R15-R24.
7. Browder T, Butterfield CE, Kraling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 2000;60:1878-1886.
8. Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med. 2002;53:409-435.
9. Aizawa Y, Kawabe J, Hasebe N, Takehara N, Kikuchi K. Pioglitazone enhances cytokine-induced apoptosis in vascular smooth muscle cells and reduces intimal hyperplasia. Circulation. 2001;104:455-460.
10. γ. Nat Med. 1998;4:1046-1052.
11. Mueller E, Sarraf P, Tontonoz P, et al. Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell. 1998;1:465-470.
12. Palakurthi SS, Aktas H, Grubissich LM, Mortensen RM, Halperin JA. Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor gamma and mediated by inhibition of translation initiation. Cancer Res. 2001;61:6213-6218.
13. Panigrahy D, Singer S, Shen LQ, et al. PPARγ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest. 2002;110:923-932.
14. Masferrer J. Approach to angiogenesis inhibition based on cyclooxygenase-2. Cancer J. 2001;7 Suppl 3:S144-S150.
15. Wang Z, Fuentes CF, Shapshay SM. Antiangiogenic and chemopreventive activities of celecoxib in oral carcinoma cell. Laryngoscope. 2002;112:839-843.
16. He TC, Chan TA, Vogelstein B, Kinzler KW. PPARδ is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell. 1999;99:335-345.
17. Gately S. The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metastasis Rev. 2000;19:19-27.
18. Wagner A, Hempel G, Boos J. Trofosfamide: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the oral treatment of cancer. Anticancer Drugs. 1997;8:419-431.
19. Blomqvist C, Wiklund T, Pajunen M, Virolainen M, Elomaa I. Oral trofosfamide: an active drug in the treatment of soft-tissue sarcoma. Cancer Chemother Pharmacol. 1995;36: 263-265.
20. Gunsilius E, Gierlich T, Mross K, Gastl G, Unger C. Palliative chemotherapy in pretreated patients with advanced cancer: oral trofosfamide is effective in ovarian carcinoma. Cancer Invest. 2001;19:808-811.
21. Amato L, Moretti S, Palleschi GM, Gallerani I, Franchi A, Fabbri P. A case of angiosarcoma of the face successfully treated with combined chemotherapy and radiotherapy. Br J Dermatol. 2000;142:822-824.
22. Maddox JC, Evans HL. Angiosarcoma of skin and soft tissue: a study of forty-four cases. Cancer. 1981;48:1907-1921.
23. Antman K, Crowley J, Balcerzak SP, et al. An intergroup Phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol. 1993;11:1276-1285.
24. Patel SR, Vadhan-Raj S, Burgess MA, et al. Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. Am J Clin Oncol. 1998;21:317-321.
25. Fata F, O'Reilly E, Ilson D, et al. Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer. 1999;86:2034-2037.
26. Arbiser JL, Panigrathy D, Klauber N, et al. The antiangiogenic agents TNP-470 and 2-methoxyestradiol inhibit the growth of angiosarcoma in mice. J Am Acad Dermatol. 1999; 40:925-929.
27. Kollmannsberger C, Brugger W, Hartmann JT, et al. Phase II study of oral trofosfamide as palliative therapy in pretreated patients with metastatic soft-tissue sarcoma. Anticancer Drugs. 1999;10:453-456.
28. Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest. 2000;105:1045-1047.